| Author | Capão, Artur | |
| Author | Oliveira, Maria L. Aguiar | |
| Author | Caetano, Braulia C. | |
| Author | Neves, Thayssa K. | |
| Author | Resende, Paola C. | |
| Author | Almeida, Walquiria A. F. | |
| Author | Miranda, Milene D. | |
| Author | Martins Filho, Olindo Assis | |
| Author | Brown, David | |
| Author | Siqueira, Marilda M. | |
| Author | Garcia, Cristiana | |
| Access date | 2022-10-11T11:00:22Z | |
| Available date | 2022-10-11T11:00:22Z | |
| Document date | 2022 | |
| Citation | CAPÃO, Artur et al. Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil. Viruses, v. 14, 1692, p. 1-18, Jul. 2022. | en_US |
| ISSN | 1999-4915 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/55095 | |
| Description | A Rede Genômica Fiocruz é formada por especialistas de todas as unidades da Fundação no país e de institutos parceiros que se empenham diariamente em gerar dados mais robustos sobre o comportamento do SARS-Cov-2 e contribuir para um melhor preparo do país no enfrentamento da pandemia em termos de diagnóstico mais precisos e vacinas eficazes. Saiba mais sobre a Rede Genômica Fiocruz em: http://www.genomahcov.fiocruz.br/ | |
| Language | eng | en_US |
| Publisher | MDPI | en_US |
| Rights | open access | |
| Subject in Portuguese | Gripe | en_US |
| Subject in Portuguese | Vacina | en_US |
| Subject in Portuguese | Imunogenicidade | en_US |
| Subject in Portuguese | Soroproteção | en_US |
| Subject in Portuguese | Soroconversão | en_US |
| Subject in Portuguese | Brasil | en_US |
| Title | Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil | en_US |
| Type | Article | |
| DOI | 10.3390/v14081692 | |
| Abstract | Annual vaccination against influenza is the best tool to prevent deaths and hospitalizations. Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high mutation rates in influenza viruses. TIV effectiveness is affected by antigenic mismatches, age, previous immunity, and other host factors. Studying TIV effectiveness annually in different populations is critical. The serological responses to Southern-Hemisphere TIV and circulating influenza strains were evaluated in 2018–2020 among Brazilian volunteers, using hemagglutination inhibition (HI) assays. Post-vaccination titers were corrected to account for pre-vaccination titers. Our population achieved >83% post-vaccination seroprotection levels, whereas seroconversion rates ranged from 10% to 46%. TIV significantly enhanced antibody titers and seroprotection against all prior and contemporary vaccine and circulating strains tested. Strong cross-reactive responses were detected, especially between H1N1 subtypes. A/Singapore/INFIMH-16-0019/2016, included in the 2018 TIV, induced the poorest response. Significant titer and seroprotection reductions were observed 6 and 12 months after vaccination. Age had a slight effect on TIV response, whereas previous vaccination was associated with lower seroconversion rates and titers. Despite this, TIV induced high seroprotection for all strains, in all groups. Regular TIV evaluations, based on regional influenza strain circulation, should be conducted and the factors affecting response studied. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil / UK Health Security Agency 61 Colindale Avenue, London NW9 5EQ, UK. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. National Influenza Center. World Health Organization. Rio de Janeiro, RJ, Brasil. | en_US |
| Subject | Influenza | en_US |
| Subject | Vaccine | en_US |
| Subject | Immunogenicity | en_US |
| Subject | Seroprotection | en_US |
| Subject | Seroconversion | en_US |
| Subject | Brazil | en_US |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
